A data-driven model of biomarker changes in sporadic Alzheimer's disease.
Alexandra L Young, Neil P Oxtoby, Pankaj Daga...
https://pubmed.ncbi.nlm.nih.gov/25012224/Actively Recruiting
Led by Washington University School of Medicine · Updated on 2026-07-27
280
Participants Needed
37
Research Sites
21 weeks
Total Duration
Researchers are evaluating remternetug, an investigational drug, to study its effects on asymptomatic individuals at risk for dominantly inherited Alzheimers disease DIAD caused by genetic mutations. The study aims to assess whether remternetug can prevent or reduce amyloid beta accumulation, a protein linked to Alzheimers progression, and to evaluate its impact on various disease biomarkers and safety. This research involves two stages Stage 1 focuses on amyloid beta changes, while Stage 2 examines downstream biomarkers related to disease progression compared to control groups. Participants will receive remternetug or a matching placebo as a subcutaneous injection every 12 weeks in a randomized, double-blind design. Following Stage 1, an open-label phase will begin after the last dose, allowing participants to receive remternetug openly. The study uses brain imaging, blood, and spinal fluid tests to monitor biomarker changes and treatment effects over time, with assessments scheduled up to 192 weeks. Participants are involved in regular visits for cognitive and clinical evaluations, brain scans using PET imaging, and collection of fluid samples to track biomarker changes. Researchers will closely monitor safety, tolerability, and cognitive measures throughout the study. The total participation duration extends over multiple years, with ongoing assessments to understand the drugs effect on disease progression and participant well-being.
CONDITIONS
A Study of a Potential Disease Modifying Treatment in Individuals at Risk for or With a Type of Early Onset AD Caused by a Genetic Mutation
J
Jamie Bartzel
E
Ellen Ziegemeier
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here
Washington University School of Medicine
Lead Sponsor
Alzheimer's Association
Collaborating Sponsor
This table compares participation in this trial with other options available for this condition. The information is drawn from published research and the trial’s study details and is provided for educational purposes only.
| Factors | Remternetug (investigational antibody) | Matching placebo (remternetug placebo injection) |
|---|---|---|
| What it is | Remternetug is an investigational anti-amyloid monoclonal antibody given as a subcutaneous injection every 12 weeks to adults with or at risk for autosomal dominant Alzheimer’s disease. | The placebo matches remternetug in appearance and is delivered as a subcutaneous injection every 12 weeks. |
| Role in trial | Active treatment arm assessing if remternetug modifies biomarkers or delays disease progression in genetically at-risk individuals before symptoms begin. | Placebo comparator, provides a baseline for understanding remternetug’s effect in pre-symptomatic individuals at risk for familial Alzheimer’s disease. |
| Primary use in the study | Studied to see if early intervention with anti-amyloid antibody can reduce amyloid load and modify biomarkers before cognitive symptoms occur. | Used as a control to compare outcomes such as amyloid load and cognitive changes against active treatment. |
| How it is given or performed | Subcutaneous injection every 12 weeks, with dosing and clinical assessments scheduled through study visits. | Subcutaneous placebo injections are given at the same frequency as the investigational arm. |
| Evidence status | Ongoing investigation; as of this trial, no published efficacy results for remternetug in pre-symptomatic autosomal dominant Alzheimer’s disease. Evidence from similar anti-amyloid antibodies suggests targeting early biomarker changes may be possible, but direct outcomes are unknown. | Placebo does not impact amyloid, biomarkers, or delay onset; serves only as a reference for observed effects in the active arm. |
| Important limitations | Long-term clinical benefit and potential risks are unknown, as results for this population are not yet published; findings from symptomatic Alzheimer’s disease may not apply to asymptomatic, genetically at-risk individuals. | Placebo does not provide clinical benefit or alter the disease course; prolonged participation may still require burdensome visits and procedures. |
Disclaimer: This comparison is created with the help of artificial intelligence(AI) and may contain errors or missing information. It is not medical advice and does not mean one option is better or safer than another. Clinical trials are still being studied, and joining a trial is your choice. Please consult your healthcare professional before making any decisions.
You may qualify if you...
You will not qualify if you...
Duration - 2 to 4 weeks
Participants are screened for eligibility to participate in the trial.
1 screening visit
Duration - Up to 192 weeks
Participants receive subcutaneous injections of remternetug or matching placebo every 12 weeks during the randomized double-blind phase.
Regular visits every 12 weeks for dosing and assessments
Duration - After last dose of Stage 1
Following the double-blind phase, participants may receive open-label remternetug treatment.
Visits scheduled for ongoing treatment and monitoring
Duration - Up to 192 weeks
Participants undergo regular assessments including brain imaging, fluid biomarker collection, and cognitive testing to monitor disease progression and safety.
Multiple visits at baseline and weeks 48, 96, 144, and 192
Study Type
INTERVENTIONAL
Masking
QUADRUPLE
Allocation
RANDOMIZED
Model
PARALLEL
Primary Purpose
TREATMENT
Number of Arms
3
Have more questions? Get in touch with our team for quick support
Alexandra L Young, Neil P Oxtoby, Pankaj Daga...
https://pubmed.ncbi.nlm.nih.gov/25012224/Gil D Rabinovici, Ansgar J Furst, Adi Alkalay...
https://pubmed.ncbi.nlm.nih.gov/20080878/Anne M Fagan, Chengjie Xiong, Mateusz S Jasielec...
https://pubmed.ncbi.nlm.nih.gov/24598588/Eric McDade, Guoqiao Wang, Brian A Gordon...
https://pubmed.ncbi.nlm.nih.gov/30217935/Davis C Ryman, Natalia Acosta-Baena, Paul S Aisen...
https://pubmed.ncbi.nlm.nih.gov/24928124/Joseph L Price, Daniel W McKeel, Virginia D Buckles...
https://pubmed.ncbi.nlm.nih.gov/19376612/J L Price, J C Morris
https://pubmed.ncbi.nlm.nih.gov/10072051/John Hardy, Dennis J Selkoe
https://pubmed.ncbi.nlm.nih.gov/12130773/Ronald B Demattos, Jirong Lu, Ying Tang...
https://pubmed.ncbi.nlm.nih.gov/23217740/John R Sims, Jennifer A Zimmer, Cynthia D Evans...
https://pubmed.ncbi.nlm.nih.gov/37459141/Washington University School of Medicine
Lead Sponsor
Alzheimer's Association
Collaborating Sponsor